Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026
Semax is a synthetic chain of seven amino acids, modelled on a fragment of the hormone ACTH, that is a registered prescription medicine in Russia (as nasal drops), is not FDA-approved, and is promoted online as a “nootropic” for focus, memory, mood and ADHD. The strongest evidence for it is in stroke: tested in people, several small Russian studies of semax given into the nose reported faster or better recovery, but none that we could read was blinded, placebo-controlled and registered in advance, so that support is low-certainty. The evidence in healthy people stops at three small studies of one dose to two days (only a 1996 study of 19 men tested attention and memory), and we found no published study of semax for ADHD, by injection, or in the modified versions sold online, such as N-acetyl semax.
This review is part of our peptide library. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.
At a glance
- FDA status
- Not FDA-approved. A draft HHS policy names semax (free base) for intranasal use only; that isn’t approval.
- Evidence in people
- Almost all Russian, small, mostly unblinded; none found registered in advance. All gave it by nose.
- The claim you’ve heard
- Sharper focus and memory: not established. One unrepeated 1996 study of 19 men, one or two days; nothing longer.
- Doses tested in people
- By nose only. Healthy adults: 0.25 to 1.2 mg. Stroke: 6 to 18 mg a day. None by injection.
- Sport
- Not named on WADA’s 2026 Prohibited List. WADA says an unnamed peptide “may still be prohibited”.
What semax is
Semax is a synthetic peptide seven amino acids long (Met-Glu-His-Phe-Pro-Gly-Pro), developed in Moscow at the Institute of Molecular Genetics of the Russian Academy of Sciences. It keeps the first four amino acids of a fragment of ACTH (adrenocorticotropic hormone) and replaces the last three. The FDA describes it as an analog of that fragment that lacks ACTH’s hormone actions; we found no study in people that measured cortisol or other hormones after semax.
In Russia. The FDA’s review records that “Semax is a registered drug in Russia and is available as 0.1% and 1% nasal drops.” We read its label in two Russian drug references and a copy of the instructions for use, not in the state register, which would not open, so it is second-hand.
One name, several substances. The FDA treats semax (free base) and semax acetate, a salt, as “different active pharmaceutical ingredients”, and says the clinical papers “do not specify whether the substance used was a free base or a salt”. Online the name also covers modified versions, chiefly N-acetyl semax and N-acetyl semax amidate: different molecules, and we found no study of either in people.
Where it stands with the FDA
Status checked: November 19, 2026.
In plain words: semax is not an FDA-approved medicine, and the FDA’s staff proposed not adding it to the list of ingredients that can be used in compounding (making a medicine for one patient on a prescription), though HHS reports that an advisory committee voted for adding it. HHS, the federal department the FDA belongs to, has announced a draft policy and said it does not intend to take enforcement action over semax (free base) compounded for intranasal use (in the nose) under its conditions; that is not approval, and the policy names no injection.
As of November 19, 2026, semax is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. In a draft interim policy announced on October 30, 2026, HHS said it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician that compounds single-ingredient semax (free base) “for intranasal use” for a patient-specific prescription when the policy’s conditions are met; HHS’s notice says the policy “is not binding on HHS or the public”, and it is not FDA approval. The FDA’s own review proposed that semax “NOT be included” on that list; HHS says the advisory committee “voted in favor of both forms”.
The FDA’s own review. In an evaluation dated May 11, 2026, the FDA’s staff wrote: “we propose not adding semax (free base) or semax acetate to the 503A Bulks List.” For “cerebral ischemia, migraine and trigeminal neuralgia” (stroke and two pain conditions) they found “insufficient evidence to support the effectiveness”, and overall “insufficient clinical information to characterize the safety profile”. They did not assess the Russian-language stroke papers, because “the full references were not available in English”.
The advisory committee. News reports say the committee voted 8 in favor, 5 against, with 1 abstention, on July 24, 2026; the FDA has published no minutes, transcript or written vote count; its recording of the meeting is online. The FDA says advisory committees make “non-binding recommendations”.
HHS’s draft interim policy. Its appendix identifies “Semax (Free Base)” only and concludes that “enforcement discretion for semax free base is appropriate for intranasal use that is compounded from API accompanied by a CoA meeting the conditions of this policy” (API: active ingredient; CoA: certificate of analysis). It names no injectable, oral or other form of semax. Its conditions include a single active ingredient, so a blend of semax with another peptide is outside it, and a prescription for one identified patient. Its text leaves two things open: the only delivery device it names is “an FDA 510(k)-cleared syringe”, with nothing on a nasal spray pump, and it gives no identity for semax acetate.
Kansas. HHS’s policy is not a Kansas rule. K.A.R. 68-13-3(d) says a pharmacist “shall not compound a nonsterile preparation” by “compounding finished drugs from bulk active ingredients that are not components of FDA-approved drugs”, and it reaches preparations shipped into Kansas. Kansas’s rules do not say whether a nasal preparation is nonsterile or sterile, and its sterile rule has no such item. The Board of Pharmacy’s guidance documents include nothing on semax or nasal preparations, so no source we read settles how these rules apply to compounded semax.
Sport. Semax is not named on WADA’s 2026 Prohibited List. Class S0 prohibits a substance that no later class covers and that has “no current approval by any governmental regulatory health authority for human therapeutic use”; WADA does not state whether it treats semax under S0 or any other class. Its note on the 2027 List: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
Claims you’ll see, and why sources disagree
Why pages disagree:
- A foreign label is read as proof. The Russian label lists ADHD in children from age 7. We found no published study of semax in ADHD, and in 2026 a Russian expert council put it among medicines “with a limited evidence base” for it.
- Animal results are written as results in people. Semax raises BDNF (a nerve-growth protein) in rat brain; in people it was measured only in the blood of stroke patients, in one unblinded study.
- One molecule and one route stand in for others. Studies of nasal drops are cited for injections and for N-acetyl semax, neither studied in people.
“Not tested in people” is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.
| Claim | Level of evidence | Verdict |
|---|---|---|
| Sharper focus and memory | Reported in people: one 1996 study of 19 healthy men, one or two days | Not established. Never repeated; nothing over weeks. |
| Raises BDNF | Animal studies; in people, blood levels in one unblinded stroke study | Accurate for rat brain. Never measured in healthy people. |
| Helps stroke recovery | Tested in people: small Russian studies, open or of unconfirmed blinding | Low-certainty support from one country; no blinded, registered trial. |
| Helps ADHD | No published study in people | No evidence in people. The FDA: “supporting literature for this use was not found”. |
| Eases stress or anxiety | Animal studies | Mixed results in rats. The Russian label advises against use in anxiety disorders. |
| Relieves pain | Reported in people: one uncontrolled study | Not supported. Its authors: “semax does not exhibit analgesic activity by itself”. |
| Safe; “well tolerated” | Reported in people | Not established. Few harms reported; “Most of the references did not discuss safety” (the FDA). |
| N-acetyl versions or injections work as well or better | Not tested in people | No evidence in people, for either. |
What the evidence consists of
Almost all of the human evidence is Russian. We read the two 2018 stroke papers below in full, most others as English abstracts, and a few only as the FDA describes them; a design detail missing below was missing from what we read.
Tested in people
These studies had a comparison group. We could confirm blinding in none, and none we read reports a confidence interval or withdrawals.
| Study | People | Design | What happened | Funding or limits |
|---|---|---|---|---|
| Gusev, 2018 | 110 adults in stroke rehabilitation | Randomized to rehabilitation with or without semax; no placebo or blinding described | Daily function (Barthel index) recovered faster: by month 1, 78.5% and 62.4% of the final gain against 43.8% and 21.9%. Blood BDNF rose more. No significant effect on muscle weakness | No conflict declared; funding not stated. Group sizes in image tables we could not read |
| Meta-analysis, 2018 | 8 trials, 654 people; 3 trials (181) met its criteria | Small Russian trials in the first 10 to 14 days after stroke; comparison called placebo in its abstract, usual therapy in its table. Trials not opened | Lower stroke-severity scores at 10 to 14 and 21 days (mild strokes: at 21 days only). One lower-dose, 5-day arm is marked no effect on all five endpoints | Authors not from the developer’s institute. Very high heterogeneity; they ask for “a multicenter, powerful double-blind study” |
| Gusev, 1997 | 30 treated, 80 controls; acute stroke | Added to conventional therapy; allocation not stated | “some influence on the rate of restoration of the damaged neurological functions”; no numbers | Abstract only; developers are co-authors |
| Lebedeva, 2018; Panikratova, 2020 | 24 and 52 healthy volunteers, possibly the same people | One dose against placebo; randomization and blinding not stated | A resting brain-scan pattern differed from placebo. No test of memory, attention or mood | Abstracts only; the developer is senior author of the first |
| Ivanikov, 2002 | 32 adults with resistant peptic ulcers | Ulcer medicines with or without semax; open | Healed by day 14: 89.5% against 30.8% | Abstract only; developers are co-authors; never repeated |
| Eye studies, 2000 to 2013 | Optic-nerve disease, glaucoma, diabetic retinopathy | Added to other treatment; allocation not stated | Better visual function, no numbers | Abstracts only |
Reported in people
These reports had no comparison group, or describe none.
| Study | People | What was given | What happened | Limits |
|---|---|---|---|---|
| Kaplan, 1996 | 19 healthy men | One dose, or one a day for 2 days | EEG changes and a “beneficial action of Semax on the work efficiency of operators”; the developers’ later review adds better attention and short-term memory. No numbers | By the developers; never repeated; abstract only |
| Koroleva, 1996, as the FDA describes it | 37 adults with migraine or facial pain | One dose | Migraine stopped in 4 of 12 and eased in 8; “no changes” in trigeminal neuralgia. The authors: “semax does not exhibit analgesic activity by itself” | The FDA: “small sample size, no blinding, no control group” |
| Serdyuk, 2007 | 27 people with ALS | Two 10-day courses, open-label | No effect on the disease; a quality-of-life score improved | Abstract only; describes no control group |
| Gusev, 2005 | 187 people with chronic poor blood supply to the brain | Not in the abstract | “significant clinical improvement” reported | Abstract only; no comparison group described |
In children, the only reports are two meeting abstracts (120 with depression, 331 with tics) in which semax was given with other treatments; we have no result for semax from either. No case report has been published.
Animal studies
The animal record is large, nearly all in rats and mice. In rats with an induced stroke, “the infarcted brain areas were approximately 20% smaller in semax-treated rats than vehicle-treated rats” (the FDA’s summary), though another rat study found that “the effect of semax decreased with increasing dose”. One nasal dose gave “a maximal 1.4-fold increase of BDNF protein levels” in the rat hippocampus. Pain relief appeared after injection into the abdomen but not after nasal dosing.
Lab studies and how it is thought to work
The FDA’s staff write that semax acts “through poorly understood mechanisms of action”. No receptor has been identified: labelled semax bound to rat brain membranes, and the binding protein was not identified (lab studies).
Who produced the research. Of the 176 PubMed records indexed under semax’s substance name on November 19, 2026, 170 (96.6%) are Russian by author affiliation, language or journal, and 91 (51.7%) list N.F. Myasoedov, of the institute that developed semax, as an author. The medicine’s manufacturer gives the same Moscow street address as that institute. No semax trial was registered at ClinicalTrials.gov or in the EU register on that date.
Dosing: what has been tested, what is used, and what the reasoning supports
This section reports and reasons; it recommends nothing. Doses have been set against each other only in Russian stroke studies of unconfirmed blinding, and semax has never been measured in human blood, so no dose can be called optimal.
Doses tested in people
Every dose in a published study was given into the nose, as drops or as drops driven by a weak electric current; the FDA was “unable to find literature that discussed administration via subcutaneous injection” (under the skin).
| Study or label | People | Dose | Route | How often and how long |
|---|---|---|---|---|
| Kaplan, 1996 | 19 healthy men | 0.25 mg, or 1 mg | Nose | Once, or daily for 2 days |
| Lebedeva, 2018; Panikratova, 2020 | Healthy adults | 1.2 mg (the FDA’s figure) | Nose | Once |
| Gusev, 1997 | 30 adults, acute stroke | 12 or 18 mg a day | Nose | 5 or 10 days |
| Trials in the 2018 meta-analysis | 654 people, acute stroke | 12 to 18 mg a day; arms at 3 and 6 mg also listed, the 6 mg, 5-day arm marked no effect | Nose | 5 to 21 days |
| Gusev, 2018 | 110 adults, stroke rehabilitation | 6 mg a day | Nose | 10 days, repeated once after a 20-day break |
| Serdyuk, 2007 | 27 adults with ALS | 12 mg a day | Nose | Two 10-day courses, 2 weeks apart |
| Russian label (a label, read second-hand; not a tested dose) | Stroke (1% drops); mental fatigue (0.1% drops) | 6,000 to 20,000 micrograms a day; 400 to 900 micrograms a day | Nose | 10 days; 3 to 5 days |
Other reports give the dose only in drops, or not at all in their abstracts; three printed figures that we could not check against their papers are left out. No dose has been tested in people by injection or by mouth, for N-acetyl semax or any other modified version, for daily use beyond about three weeks (two days in healthy people), or with the spray pumps in which compounded and online products are supplied.
Doses in common use
These are amounts in circulation: practice that no trial set, reported so that a reader can see where each comes from and how it compares with what was studied.
- A few hundred micrograms a day into the nose, for weeks: the dominant figure online. A telehealth and compounding marketing article gives “between 250 and 600 mcg per day” in “longer cycles of 4 to 8 weeks, followed by 2 to 4 weeks off”; a protocol-aggregator page gives “200 to 600 mcg daily”. No trial set either. The amounts sit inside the Russian 0.1% label’s range and near the 1996 volunteer study; the durations have no study behind them.
- The same micrograms by injection, and for N-acetyl semax. A dose-chart site for injectable vials gives “200–600 mcg per day” and says of it: “Research-community convention, not trial data”. The marketing article says the ranges “are comparable across all three” forms. No trial set either, and nothing compares: no human study has used an injection or a modified form.
What the pharmacology supports, and what it doesn’t
- Amount (not measured in people; measured in animals). The FDA’s staff “were not able to find pharmacokinetic studies in humans”, so how much of a dose reaches human blood or brain is unknown; the Russian label’s figure of 60 to 70% absorbed from the nose cites no study (claimed, not confirmed). In rats, well under 0.1% of a nasal dose was found in the brain, and one rat study found less effect at higher doses, so more cannot be assumed to do more.
- How often (cannot be derived). No half-life has been measured in people. The developers’ own review prints two incompatible figures, “a few minutes” and “>1 h”, and describes effects lasting 20 to 24 hours after one dose (claimed); the Russian label nonetheless gives two to five doses a day (convention). These pull in different directions and support no schedule.
- Route and form (measured in animals; inferred). In rats, about fourteen times more of a dose reached the brain by the nose than by a vein (the FDA’s figures), and pain relief appeared only after injection into the abdomen. So a nasal result says nothing about an injection; and in one cell experiment acetylating semax removed a protective effect, so nothing known of semax can be assumed for N-acetyl semax. What a spray pump delivers per use has no published data.
- Duration and monitoring (convention; inferred). Labelled Russian courses run 3 to 14 days (30 for the children’s use); tolerance, dependence and long use have not been studied. What a prescriber would watch follows from the safety signals below.
Nobody knows how much of a nasal dose reaches the human brain, how long it acts, or what weeks of use do.
What common protocols get wrong
- Days of study are stretched to weeks. Cycles of 4 to 8 weeks are 14 to 28 times the two days studied in healthy people; the marketing article describing them says continuous use “hasn’t been formally studied in Western research”.
- Stroke doses are misreported, and borrowed. The marketing article gives “Russian stroke recovery protocols” as “1,000 to 1,500 mcg per day”; the studies and the label state 6,000 to 20,000 micrograms a day. Nothing links hospital stroke doses to use by healthy people.
- A label line is presented as research. The same article says “ADHD adjunct research” has “explored the 250 to 500 mcg per day range in pediatric and adolescent populations”; no such study is in PubMed, and the figures resemble the Russian label’s amount for children.
The dose is the prescriber’s decision for one patient.
Safety, and who should be most cautious
Few harms have been reported, and few studies looked: the FDA’s staff found that “Most of the references did not discuss safety”. An absence of reports from such studies is weak evidence of safety.
Reported in people. The 2018 stroke study reported no side effects, without saying how they were collected. The Russian label lists mild irritation of the nose with long use; the developers’ review adds “discoloration of the mucous membrane of the nasal cavity in 10% of patients and a mild increase in the concentration of glucose in the blood of 7.4% of patients with diabetes”, denominators not given. The FDA’s adverse-event database holds one unverified report: a consumer had eye pain and burning after using “Semax 0.1% nasal drops purchased online”, was hospitalized, and a year later said the pain had not resolved.
The FDA’s concerns, and HHS’s reply. People who take blood thinners or stimulant medicines have the most reason for caution, on animal evidence and theory. In rats semax made blood slower to clot, and the FDA writes of “concern about the risk of bleeding”. In mice it amplified amphetamine’s release of dopamine, “a response typically induced by drugs of abuse such as cocaine”. HHS replies that these concerns “are mechanistic rather than observed”, citing an intranasal record of “several hundred subjects with no reported adverse outcome”. Both fit the same record: no harm was reported, and most studies did not report whether they looked.
Injection and animal safety studies. The FDA: “There are no safety data for semax (free base) and semax acetate administered by the proposed SC ROA” (injection under the skin). It also “did not identify” animal studies of acute or repeat-dose toxicity, reproductive effects or cancer risk.
| Situation | What is known | Basis |
|---|---|---|
| Pregnancy and breastfeeding | No human data; contraindicated on the Russian label because no clinical studies were done | Russian label (second-hand); the FDA’s review |
| Under 18 | Russian 1% drops contraindicated; 0.1% drops contraindicated under 7. No published trial in children found | Russian label |
| Seizures in the past | Contraindicated on the Russian label. In some brain-injured patients EEG showed “episodes of paroxysmal activity” after a dose | Russian label; reported in people |
| Anxiety disorders, acute psychiatric illness | Contraindicated on the Russian label, which gives no reason | Russian label |
| Blood thinners; stimulant medicines | Slower clotting in rats; amplified amphetamine effects in rodents. No bleeding reported in people; no human data on stimulants | Animal studies; theory |
| Diabetes | “a mild increase” in blood glucose in 7.4% of patients with diabetes | Reported in people (developers’ review) |
Product quality
- What the FDA found. Both forms are “not well-characterized”: the certificates of analysis it saw had “no testing results for the quality control attribute on aggregates, microbial bioburden and bacterial endotoxin levels” (clumped peptide, germs and bacterial toxins).
- What HHS says has changed. HHS writes that certificates “from FDA-registered sources supply the endotoxin result” and “a declared salt form”. They are not public, so we cannot check them.
- Which substance, in what device. The FDA: “None of the websites searched indicate whether their marketed products contain the base or a salt or ester of semax.” It found semax sold “for research purposes only”, with “nasal spray and subcutaneous injection as common methods of administration”, and “would have strong concerns” about a compounded nasal spray for lack of information on the pump.
- Independent testing. We found no published measurement of the purity or content of semax sold online; a Belgian government laboratory that found it in seized products calls such peptides “potentially dangerous molecules”.
What we make of it
This section is our reading of the evidence. It is a judgment, not a finding.
For recovery after ischemic stroke, semax by nose, as given in Russian hospitals, is plausible but unconfirmed. Several studies point the same way and the animal models agree; but they were small, none we could read was blinded, we found none registered in advance, the results on dose do not line up, and nearly all the research comes from the institutes that developed and make the medicine. That is a reason for caution, not for dismissal. The meta-analysis’s own authors asked for a large double-blind trial; none has been published or registered.
For what a healthy person is offered, semax is unproven and experimental. Weeks of use for focus or memory rest on a two-day study of 19 men, ADHD has no published study, and the injected and acetylated products have never been studied in a person. A benefit is not ruled out; it has not been measured, and neither has the cost of weeks of use.
A blinded, placebo-controlled, registered trial with a clinical outcome would change our reading. For whom, after what, with what monitoring and when to stop are our Medical Director’s to state.
Peptide care at Rock Creek Wellness
Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.
So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.
What would change this review
- A blinded, placebo-controlled trial registered in advance, a study of semax in human blood, or an independent analysis of products sold online.
- A final rule. HHS’s draft policy is written to last “Until a peptide bulk drug substance is addressed in a final rule”.
Common questions
Does semax work?
For stroke recovery, possibly: small Russian studies reported a benefit, but none we could read was blinded and registered in advance. In healthy people it has not been tested beyond two days, and for ADHD we found no published study.
Is semax safe?
That is not established. Few harms have been reported, but most studies did not report whether they looked, and none gave semax for longer than about three weeks. Injected semax has no safety data in people.
Is semax FDA-approved?
No. It is not an FDA-approved drug or a component of one. Its registration in Russia says nothing about its status here, and HHS’s draft policy is not an approval.
Can a doctor prescribe semax?
The FDA and HHS documents we read give no yes or no: their conditions attach to the compounding and the product, not to the prescription. Semax is not FDA-approved, so a prescription would be for a compounded medicine, and state pharmacy rules apply separately.
How much semax do people use, and how often?
In studies, healthy adults got 0.25 to 1.2 mg into the nose, once or for two days, and stroke patients 6 to 18 mg a day for 5 to 14 days. Websites commonly state a few hundred micrograms a day for weeks, which is practice no trial set.
Sources
Show all 44 sourcesHide sources
- FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026: Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate). FDA, 2026.
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. HHS, 2026.
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA, 2026.
- The PEPTIDE-L Wave Rolls On! PCAC Adds Two More Bulk Drug Substances for the 503A List. Hyman, Phelps & McNamara (FDA Law Blog), 2026.
- FDA committee recommends looser restrictions for several peptides. Healio, 2026.
- K.A.R. 68-13-3, Nonsterile preparations. Kansas Secretary of State, 2018.
- K.A.R. 68-13-4, Sterile preparations and K.A.R. 68-13-2, Definitions. Kansas Secretary of State, 2018.
- Board of Pharmacy, Reports & Guidance Docs. Kansas Board of Pharmacy, read 2026.
- The Prohibited List (the 2026 List; Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List). World Anti-Doping Agency, 2025 and 2026.
- Семакс (Semax), капли назальные 0.1%: описание препарата. Справочник Видаль (Vidal drug reference, Russia), 2021.
- Семакс (Semax), капли назальные 1%: описание препарата. Справочник Видаль (Vidal drug reference, Russia), 2021.
- Семакс: инструкция по применению, капли назальные 0.1% и 1%. Регистр лекарственных средств России (RLS), 2026.
- Семакс, капли назальные 1%: инструкция по применению (регистрационный номер Р N000812/01). medi.ru (a copy of the instructions for use), 2016.
- ClinicalTrials.gov API, search “semax” and EU Clinical Trials Register, search “semax”. NIH and EMA, searched 2026.
- PubMed search for the substance name “ACTH (4-7), Pro-Gly-Pro-“. US National Library of Medicine, searched 2026.
- A New Generation of Drugs: Synthetic Peptides Based on Natural Regulatory Peptides. Neuroscience & Medicine, 2013.
- Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics, 2022.
- Мета-анализ: эффективность Семакса в остром периоде ишемического инсульта (Meta-Analysis: Semax Effectiveness in the Acute Period of Stroke). Вестник восстановительной медицины (Bulletin of Rehabilitation Medicine), 2018.
- Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents. Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova, 2026.
- Эффективность семакса при лечении больных на разных стадиях ишемического инсульта (The efficacy of semax in the treatment of patients at different stages of ischemic stroke). Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova, 2018.
- Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova, 1997.
- Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova, 2005.
- Effects of Semax on the Default Mode Network of the Brain. Bulletin of Experimental Biology and Medicine, 2018.
- Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences, 2020.
- Synthetic ACTH analogue SEMAX displays nootropic-like activity in humans. Neuroscience Research Communications, 1996.
- Therapy of peptic ulcer with semax peptide. Bulletin of Experimental Biology and Medicine, 2002.
- Study of the analgesic effect of the semax preparation. Biulleten Eksperimentalnoi Biologii i Meditsiny, 1996.
- Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziologiia i Reanimatologiia, 1999.
- The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zhurnal Nevrologii i Psikhiatrii imeni S S Korsakova, 2007.
- Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestnik Oftalmologii, 2000.
- Semax in the treatment of glaucomatous optic neuropathy in patients with normalized ophthalmic tone. Vestnik Oftalmologii, 2001.
- The results of the application of the pre-formed physical factors and neuroprotective therapy for the rehabilitative treatment of the patients with diabetic retinopathy. Voprosy Kurortologii, Fizioterapii i Lechebnoi Fizicheskoi Kultury, 2013.
- Cognitive impairments in children with tic disorders and Tourette syndrome. Movement Disorders, 2016.
- Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 2006.
- Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 2006.
- Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 2005.
- Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganicheskaia Khimiia, 2006.
- Nootropic and analgesic effects of Semax following different routes of administration. Rossiiskii Fiziologicheskii Zhurnal imeni I M Sechenova, 2010.
- Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. European Journal of Pharmacology, 2024.
- Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry, 2016.
- Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions. Bulletin of Experimental Biology and Medicine, 2001.
- Effect of semax and mexidol on brain ischemia models in rats. Eksperimentalnaia i Klinicheskaia Farmakologiia, 2009.
- The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis, 2020.
